While
Paclitaxel treatment alone can lead to a decrease in tumor size, there is a large risk of relapse once the treatment is terminated.
It's injected directly into the peritoneum through a catheter, which exposes the tumors to higher concentrations of the drug compared to standard IV
paclitaxel treatment.
Not exact matches
Nanotax works by flipping the script on how
paclitaxel is administered to patients and with how it's formulated, potentially making it a more effective and better tolerated
treatment for ovarian and other abdominal cancers.
After five weeks, the combination
treatment in the six mice decreased tumor size by up to 66 percent, compared with six mice treated with only
paclitaxel.
Paclitaxel and another chemotherapy drug, carboplatin, are considered standard, first - line
treatments for advanced ovarian cancer, experts say, and most patients respond to the drugs initially.
The drug, known under the brand name Nanotax, is a fine particle reformulation of
paclitaxel, the standard
treatment for ovarian cancer.
When p21 is produced, no synergy occurs with
paclitaxel; therefore, there is no benefit of adding the HDAC inhibitor to
treatment.
In testing multiple HDAC inhibitors in combination with the chemotherapy drug
paclitaxel, known to give some benefit for this aggressive cancer, they found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy
treatment.
When he and his colleagues gave the mice the standard, maximum tolerated dose of the chemotherapy drug
paclitaxel, the tumours roared back as soon as the
treatment was stopped.
TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line
treatment adding it to carboplatin /
paclitaxel.
Combining
Paclitaxel with Nutlin - 3 not only potentiated the tumor response to
Paclitaxel, but also prevented Numb - deficient tumors from re-growing after
treatment discontinuation.
They confirmed this by showing that tumor growth was reduced in mice treated with an antibody drug that targets TIM - 3 and the chemotherapy agent
paclitaxel, as compared to
treatment with
paclitaxel alone.
One example of the new metronomic regimen, in this instance, is use of two drugs already common in ovarian cancer
treatment —
paclitaxel and rapamycin — but at levels a tenth to a third of the maximum tolerable dose.
First - line
treatment for ovarian cancer includes surgery followed by a chemotherapy regimen combining a platinum - based (usually carboplatin) and a taxane - based (usually
paclitaxel)
treatment, which achieves a complete response in approximately 80 % of patients.
Paclitaxel, the first of a class of drugs known as taxanes, is approved by the FDA for the
treatment of advanced ovarian cancer.
In the case of prostate cancer, for which a chemotherapeutic agent called
paclitaxel was used, the team observed an flourescence increase of 400 percent in tumors that were sensitive to the
treatment.
To uncover how groups of cancer cells achieve functional diversity (through RNA) to survive chemotherapy, Lopez - Diaz dosed dishes of human pre-cancer and metastatic breast cancer cells with the cancer drug
paclitaxel for a week and then removed the drug for a few weeks, mimicking the
treatment cycle for a cancer patient.
RNA - sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined
treatments of cisplatin with
paclitaxel and docetaxel.
PULLMAN — Washington State University and Exelixis Plant Sciences, Inc., have entered a commercial licensing agreement covering patent rights and biological materials for use of plant cell cultures in the production of
paclitaxel and other valuable taxane products used in cancer
treatments.
Because they suppress cell division,
paclitaxel and other taxanes are important therapeutic compounds for the
treatment of cancer and other the diseases.
Paclitaxel (Taxol ®) is a widely - used anticancer agent for
treatment of ovarian, breast, lung, head, and neck cancer with two serious side effects: myelosuppression and peripheral sensory neurotoxicity which limits its use in high / cumulative doses or in combination with other anticancer agents.
Paclitaxel has been used in the
treatment of cancer in humans for more than 20 years, and is now beginning to see circulation in its veterinary form.